Additionally, effective tumor responses from CETN1 targeted radiation might not even require the administration of high radionuclide doses, since the radiolabeled antibody will not be “wasted” by targeting the antigen on the healthy tissue rather than concentrate in the tumor. This evidence concerns the gene CETN1 and neoplasm.